GSA Capital Partners’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$252K Buy
820,312
+765,728
+1,403% +$194K 0.01% 1487
2026
Q2
$12K Buy
54,584
+4,742
+10% +$2.86K ﹤0.01% 1688
2026
Q1
$28K Buy
+49,842
New +$30.3K ﹤0.01% 1633
2025
Q4
– Sell
-31,486
Closed -$112K – 2126
2025
Q3
$112K Buy
+31,486
New +$94.1K 0.01% 1511
2023
Q4
– Sell
-46,782
Closed -$245K – 1976
2023
Q3
$245K Sell
46,782
-152,034
-76% -$675K 0.02% 1193
2023
Q2
$372K Buy
198,816
+156,309
+368% +$548K 0.04% 921
2023
Q1
$159K Sell
42,507
-127,338
-75% -$668K 0.02% 1298
2022
Q4
$525K Sell
169,845
-4,231
-2% -$15.9K 0.07% 570
2022
Q3
$794K Buy
174,076
+169,478
+3,686% +$1.68M 0.11% 265
2022
Q2
$121K Buy
4,598
+2,132
+86% +$75.3K 0.02% 1190
2022
Q1
$92K Buy
+2,466
New +$108K 0.01% 1303
2021
Q4
– Sell
-1,066
Closed -$88K – 1835
2021
Q3
$88K Buy
+1,066
New +$92.6K 0.01% 1333

Other funds holding VTGN

GSA Capital Partners's VTGN Position: Q3 2026 in Review

GSA Capital Partners increased its VistaGen Therapeutics (VTGN) stake by 1,403% in Q3 2026, buying an estimated $194K and bringing the position to 820,312 shares worth $252K. The position accounts for 0.01% of the portfolio, ranked #1487.

GSA Capital Partners first reported a position in VTGN in Q3 2021 and has held it in 12 quarters since. The position peaked at $794K in Q3 2022. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.

  • GSA Capital Partners held 820,312 shares of VistaGen Therapeutics worth $252K as of Q3 2026.
  • GSA Capital Partners bought 765,728 VistaGen Therapeutics shares in Q3 2026, an estimated $194K.
  • VistaGen Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1487 holding.
  • GSA Capital Partners first reported a position in VistaGen Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • GSA Capital Partners's VistaGen Therapeutics position peaked at $794K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.